Eli Lilly taps blue-chip bond market to fund Morphic acquisition
Lilly is buying Morphic for $3.2 billion to gain experimental therapies for inflammatory bowel disease and other chronic illnesses.
Health Care & Insurance
Articles
Rokita dismisses IU Health privacy case
Indiana Attorney General Todd Rokita’s office in its own dismissal filing said the case was no longer necessary because discovery in the case has shown IU Health has taken actions to satisfy deficiencies in its policies.
Indiana, 14 other states sue to block Biden effort to help migrants get health coverage
The states hope to block a rule that is expected to allow 100,000 immigrants brought to the U.S. illegally as children to enroll next year in the federal Affordable Care Act’s health insurance.
Novo Nordisk’s Wegovy sales hit by competition from Eli Lilly
Novo is vying with Indianapolis-based Lilly for supremacy in the pharmaceutical industry’s fastest-growing new business, obesity drugs. The market is expected to reach $130 billion by the end of the decade.
Highly anticipated Indiana All Payer Claims Database launched
The Indiana All Payer Claims Database website is expected to provide transparency to health care costs and allow consumers to compare prices across multiple health systems.
Fast-growing MBX Biosciences raises another $63.5 million in funding
MBX is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, such as hypoparathyroidism, post-bariatric hypoglycemia and obesity.
Tech startup Arrive recruits former Carmel mayor, Elevance CFO
The two additions could help Arrive AI—a maker of smart mailboxes with security and temperature-control features—to gain more traction with municipalities and health care providers.
Charitable care from Hoosier not-for-profit hospitals remains stagnant while revenue increases
Meanwhile, health care systems continue to send thousands of Hoosiers to court over unpaid sums as small as $250.
IU Health operating income falls 73% in first six months of 2024
Indiana University Health, one of the state’s largest hospital systems, saw patient volumes and revenue grow in the first six months of the year, but saw operating income fall as the costs of labor, supplies and drugs increased to meet higher demand for surgeries and patient care.
Boar’s Head expands recall to include 7M more pounds of deli meats
The recalls are tied to an ongoing outbreak of listeria poisoning that has killed two people and sickened nearly three dozen in 13 states, according to the U.S. Centers for Disease Control and Prevention.
Groups launch hospital-linked violence intervention program
The program aims to reduce the likelihood of future violence by engaging victims of gun violence and their families with long-term services and support.
Plaintiffs push back against state’s legal response in HIP lawsuit
Plaintiffs rejected a state motion to reinstate its authority to impose premium-like charges on Medicaid beneficiaries under the Healthy Indiana Plan, urging the court to reject the state’s arguments.
Novo’s diabetes drug shows mixed results in Alzheimer’s trial
Victoza yielded mixed results in a mid-stage study of Alzheimer’s disease, failing to meet its primary goal while showing hints that larger trials of similar drugs may be successful.
Trilogy Health to expand senior housing in Noblesville, Mooresville, Greenfield
The expansion projects in three central Indiana communities are part of a larger investment the company said it is making across the Midwest to senior living and assisted living services in Indiana, Kentucky, Michigan and Ohio.
Blood test for colon cancer screening approved by regulators
The test isn’t a replacement for colonoscopies, but provides a noninvasive approach to screening.
Blood tests for Alzheimer’s might be coming to your doctor’s office.
Researchers reported Sunday that new blood tests were 91% accurate in detecting Alzheimer’s disease, far more accurate than a diagnosis from primary care doctors and specialists.
Community Health sees 44% drop in first-half operating income
Despite the decrease, Community Health Network saw an increase in admissions, emergency visits, deliveries and physician outpatient visits during the first six months of 2024.
How Lilly wooed Massachusetts biotech with flurry of offers
It was a mating dance that lasted more than three years. At the end, Eli Lilly and Co. wound up buying a Massachusetts-based biotech developing treatments for inflammatory bowel disease for $3.2 billion.
Hims & Hers adds longtime Novo executive to board amid weight-loss bet
Shortages of brand-name drugs made by Novo and Eli Lilly and Co. have allowed pharmacies to make what are essentially copies, and telehealth companies like Hims are selling them to patients at a steep discount.
Lilly shares slide 7% after Roche announces obesity pill test results
The Roche drug is a once-daily pill, compared to Lilly’s tirzepatide, sold under the brand names Mounjaro (for diabetes) and Zepbound (for obesity), which is a once-weekly shot.